Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Molecular Pharmacology
  4. Volume 17, Issue 1
  5. Article
Volume 17, Issue 1
  • ISSN: 1874-4672
  • E-ISSN: 1874-4702
file format text download EPUB
file format pdf download PDF
side by side viewer icon HTML

Abstract

Objective

Esophageal carcinoma (ESCA) is a common malignancy characterized by high morbidity and mortality. Our work managed to dissect the modulatory mechanism of E2F1/miR-29c-3p/COL11A1 in the malignant progression and sensitivity of ESCA cells to sorafenib.

Methods

bioinformatics approaches, we identified the target miRNA. Subsequently, CCK-8, cell cycle analysis, and flow cytometry were used to check the biological influences of miR-29c-3p on ESCA cells. TransmiR, mirDIP, miRPathDB, and miRDB databases were used as tools for the prediction of upstream transcription factors and downstream genes of miR-29c-3p. The targeting relationship of genes was detected RNA immunoprecipitation and chromatin immunoprecipitation, which was further validated by dual-luciferase assay. Finally, experiments revealed the way E2F1/miR-29c-3p/COL11A1 affected sorafenib’s sensitivity, and experiments were used to verify the way E2F1 and sorafenib impacted ESCA tumor growth.

Results

miR-29c-3p, downregulated in ESCA, could suppress ESCA cell viability, arrest the cell cycle in the G0/G1 phase, and impel apoptosis. E2F1 was found to be upregulated in ESCA and it could abate the transcriptional activity of miR-29c-3p. COL11A1 was found to be a downstream target of miR-29c-3p to enhance cell viability, induce cell cycle arrest in S phase, and constrain apoptosis. Cellular and animal experiments together demonstrated that E2F1 abated the sorafenib’s sensitivity of ESCA cells miR-29c-3p/COL11A1.

Conclusion

E2F1 affected the viability, cell cycle, and apoptosis of ESCA cells by modulating miR-29c-3p/COL11A1, and it attenuated the sensitivity of ESCA cells to sorafenib, shedding new light on the treatment of ESCA.

© 2024 The Author(s). Published by Bentham Science Publisher.
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Loading

Article metrics loading...

/content/journals/cmp/10.2174/1874467216666230306101653
2023-05-04
2024-11-23

  • From This Site

    /content/journals/cmp/10.2174/1874467216666230306101653
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/cmp/17/1/CMP-17-E060323214360.html?itemId=/content/journals/cmp/10.2174/1874467216666230306101653&mimeType=html&fmt=ahah

References

  1. LiuH. ZhangQ. LouQ. ZhangX. CuiY. WangP. YangF. WuF. WangJ. FanT. LiS. Differential Analysis of lncRNA, miRNA and mRNA Expression Profiles and the Prognostic Value of lncRNA in Esophageal Cancer.Pathol. Oncol. Res.20202621029103910.1007/s12253‑019‑00655‑830972633
     [Google Scholar]
  2. SungH. FerlayJ. SiegelR.L. LaversanneM. SoerjomataramI. JemalA. BrayF. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J. Clin.202171320924910.3322/caac.2166033538338
     [Google Scholar]
  3. AbnetC.C. ArnoldM. WeiW.Q. Epidemiology of esophageal squamous cell carcinoma.Gastroenterology2018154236037310.1053/j.gastro.2017.08.02328823862
     [Google Scholar]
  4. ArnoldM. SoerjomataramI. FerlayJ. FormanD. Global incidence of oesophageal cancer by histological subtype in 2012.Gut201564338138710.1136/gutjnl‑2014‑30812425320104
     [Google Scholar]
  5. TorreL.A. BrayF. SiegelR.L. FerlayJ. Lortet-TieulentJ. JemalA. Global cancer statistics, 2012.CA Cancer J. Clin.20156528710810.3322/caac.2126225651787
     [Google Scholar]
  6. ZhangK. ZhangB. BaiY. DaiL. E2F1 promotes cancer cell sensitivity to cisplatin by regulating the cellular DNA damage response through miR-26b in esophageal squamous cell carcinoma.J. Cancer202011230131010.7150/jca.3398331897226
     [Google Scholar]
  7. KuG.Y. Systemic therapy for esophageal cancer: chemotherapy.Chin. Clin. Oncol.2017654910.21037/cco.2017.07.0629129089
     [Google Scholar]
  8. WangG. GuoS. ZhangW. LiZ. XuJ. LiD. WangY. ZhanQ. a comprehensive analysis of alterations in dna damage repair pathways reveals a potential way to enhance the radio-sensitivity of esophageal squamous cell cancer.Front. Oncol.20201057571110.3389/fonc.2020.575711 33178606
     [Google Scholar]
  9. ZhangK. DaiL. ZhangB. XuX. ShiJ. FuL. ChenX. LiJ. BaiY. miR-203 is a direct transcriptional target of E2F1 and causes G1 arrest in esophageal cancer cells.J. Cell. Physiol.2015230490391010.1002/jcp.24821 25216463
     [Google Scholar]
  10. CamH. DynlachtB.D. Emerging roles for E2F: beyond the G1/S transition and DNA replication.Cancer Cell20033431131610.1016/S1535‑6108(03)00080‑1 12726857
     [Google Scholar]
  11. ChenH.Z. TsaiS.Y. LeoneG. Emerging roles of E2Fs in cancer: an exit from cell cycle control.Nat. Rev. Cancer200991178579710.1038/nrc2696 19851314
     [Google Scholar]
  12. PolagerS. GinsbergD. p53 and E2f: partners in life and death.Nat. Rev. Cancer200991073874810.1038/nrc271819776743
     [Google Scholar]
  13. LiB. XuW.W. GuanX.Y. QinY.R. LawS. LeeN.P. ChanK.T. TamP.Y. LiY.Y. ChanK.W. YuenH.F. TsaoS.W. HeQ.Y. CheungA.L. Competitive Binding Between Id1 and E2F1 to Cdc20 Regulates E2F1 Degradation and Thymidylate Synthase Expression to Promote Esophageal Cancer Chemoresistance.Clin. Cancer Res.20162251243125510.1158/1078‑0432.CCR‑15‑119626475334
     [Google Scholar]
  14. HeS. FengM. LiuM. YangS. YanS. ZhangW. WangZ. HuC. XuQ. ChenL. ZhuH. XuN. P21-activated kinase 7 mediates cisplatin-resistance of esophageal squamous carcinoma cells with Aurora-A overexpression.PLoS One2014912e11398910.1371/journal.pone.0113989 25436453
     [Google Scholar]
  15. HanD.L. WangL.L. ZhangG.F. YangW.F. ChaiJ. LinH.M. FuZ. YuJ.M. MiRNA-485-5p, inhibits esophageal cancer cells proliferation and invasion by down-regulating O-linked N-acetylglucosamine transferase.Eur. Rev. Med. Pharmacol. Sci.201923728092816 31002132
     [Google Scholar]
  16. WangZ. LiT.E. ChenM. PanJ.J. ShenK.W. miR-106b-5p contributes to the lung metastasis of breast cancer via targeting CNN1 and regulating Rho/ROCK1 pathway.Aging20201221867188710.18632/aging.102719 31986487
     [Google Scholar]
  17. FuH. ZhangJ. PanT. AiS. TangL. WangF. miR378a enhances the sensitivity of liver cancer to sorafenib by targeting VEGFR, PDGFRbeta and cRaf.Mol. Med. Rep.20181734581458810.3892/mmr.2018.8390 29328399
     [Google Scholar]
  18. LiL. ShouH. WangQ. LiuS. Investigation of the potential theranostic role of KDM5B/miR-29c signaling axis in paclitaxel resistant endometrial carcinoma.Gene2019694768210.1016/j.gene.2018.12.07630658067
     [Google Scholar]
  19. HuZ. CaiM. ZhangY. TaoL. GuoR. miR-29c-3p inhibits autophagy and cisplatin resistance in ovarian cancer by regulating FOXP1/ATG14 pathway.Cell Cycle202019219320610.1080/15384101.2019.170453731885310
     [Google Scholar]
  20. ZhouB. LuQ. LiuJ. FanL. WangY. WeiW. WangH. SunG. Melatonin increases the sensitivity of hepatocellular carcinoma to sorafenib through the perk-atf4-beclin1 pathway.Int. J. Biol. Sci.20191591905192010.7150/ijbs.3255031523192
     [Google Scholar]
  21. LiuH. WangX. ShiG. JiangL. LiuX. Tiam1 siRNA enhanced the sensitivity of sorafenib on esophageal squamous cell carcinoma in vivo.Tumour Biol.20143588249825810.1007/s13277‑014‑2083‑x24852430
     [Google Scholar]
  22. KnollS. EmmrichS. PutzerB.M. The E2F1-miRNA cancer progression network.Adv. Exp. Med. Biol.201377413514710.1007/978‑94‑007‑5590‑1_823377972
     [Google Scholar]
  23. ChangY.S. AdnaneJ. TrailP.A. LevyJ. HendersonA. XueD. BortolonE. IchetovkinM. ChenC. McNabolaA. WilkieD. CarterC.A. TaylorI.C. LynchM. WilhelmS. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models.Cancer Chemother. Pharmacol.200759556157410.1007/s00280‑006‑0393‑417160391
     [Google Scholar]
  24. LiuL. CaoY. ChenC. ZhangX. McNabolaA. WilkieD. WilhelmS. LynchM. CarterC. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.Cancer Res.20066624118511185810.1158/0008‑5472.CAN‑06‑137717178882
     [Google Scholar]
  25. YuC. FridayB.B. LaiJ.P. YangL. SarkariaJ. KayN.E. CarterC.A. RobertsL.R. KaufmannS.H. AdjeiA.A. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways.Mol. Cancer Ther.2006592378238710.1158/1535‑7163.MCT‑06‑023516985072
     [Google Scholar]
  26. YangC. DongZ. HongH. DaiB. SongF. GengL. LuJ. YangJ. SuiC. XuM. Circfn1 mediates sorafenib resistance of hepatocellular carcinoma cells by sponging mir-1205 and regulating e2f1 expression.Mol. Ther. Nucleic Acids20202242143310.1016/j.omtn.2020.08.039 33230446
     [Google Scholar]
  27. HuangF.L. YuS.J. Esophageal cancer: Risk factors, genetic association, and treatment.Asian J. Surg.201841321021510.1016/j.asjsur.2016.10.00527986415
     [Google Scholar]
  28. XiaX. LiuZ. QinQ. DiX. ZhangZ. SunX. GeX. Long-Term Survival in Nonsurgical Esophageal Cancer Patients Who Received Consolidation Chemotherapy Compared With Patients Who Received Concurrent Chemoradiotherapy Alone: A Systematic Review and Meta-Analysis.Front. Oncol.20211060465710.3389/fonc.2020.60465733489910
     [Google Scholar]
  29. DaiK.Y. YuY.C. LeuY.S. ChiC.W. ChanM.L. TsaiC.H. LinH.C. HuangW.C. ChenY.J. Neoadjuvant chemoradiotherapy and larynx-preserving surgery for cervical esophageal cancer.J. Clin. Med.20209210.3390/jcm9020387 32024132
     [Google Scholar]
  30. FengS. LuoS. JiC. ShiJ. miR-29c-3p regulates proliferation and migration in ovarian cancer by targeting KIF4A.World J. Surg. Oncol.202018131510.1186/s12957‑020‑02088‑z33261630
     [Google Scholar]
  31. ChenC. HuangZ. MoX. SongY. LiX. LiX. ZhangM. RETRACTED ARTICLE: The circular RNA 001971/miR-29c-3p axis modulates colorectal cancer growth, metastasis, and angiogenesis through VEGFA.J. Exp. Clin. Cancer Res.20203919110.1186/s13046‑020‑01594‑y32430042
     [Google Scholar]
  32. WuH. ZhangW. WuZ. LiuY. ShiY. GongJ. ShenW. LiuC. miR-29c-3p regulates DNMT3B and LATS1 methylation to inhibit tumor progression in hepatocellular carcinoma.Cell Death Dis.20191024810.1038/s41419‑018‑1281‑730718452
     [Google Scholar]
  33. WangL. YuT. LiW. LiM. ZuoQ. ZouQ. XiaoB. The miR-29c-KIAA1199 axis regulates gastric cancer migration by binding with WBP11 and PTP4A3.Oncogene201938173134315010.1038/s41388‑018‑0642‑030626935
     [Google Scholar]
  34. FischerH. StenlingR. RubioC. LindblomA. Colorectal carcinogenesis is associated with stromal expression of COL11A1 and COL5A2.Carcinogenesis200122687587810.1093/carcin/22.6.87511375892
     [Google Scholar]
  35. BadeaL. HerleaV. DimaS.O. DumitrascuT. PopescuI. Combined gene expression analysis of whole-tissue and microdissected pancreatic ductal adenocarcinoma identifies genes specifically overexpressed in tumor epithelia.Hepatogastroenterology200855882016202719260470
     [Google Scholar]
  36. ChongI.W. ChangM.Y. ChangH.C. YuY.P. SheuC.C. TsaiJ.R. HungJ.Y. ChouS.H. TsaiM.S. HwangJ.J. LinS.R. Great potential of a panel of multiple hMTH1, SPD, ITGA11 and COL11A1 markers for diagnosis of patients with non-small cell lung cancer.Oncol. Rep.200616598198810.3892/or.16.5.98117016581
     [Google Scholar]
  37. LiA. LiJ. LinJ. ZhuoW. SiJ. COL11A1 is overexpressed in gastric cancer tissues and regulates proliferation, migration and invasion of HGC-27 gastric cancer cells in vitro.Oncol. Rep.201737133334010.3892/or.2016.5276 28004111
     [Google Scholar]
  38. WuY.H. HuangY.F. ChangT.H. ChouC.Y. Activation of TWIST1 by COL11A1 promotes chemoresistance and inhibits apoptosis in ovarian cancer cells by modulating NF-kappaB-mediated IKKbeta expression.Int. J. Cancer2017141112305231710.1002/ijc.3093228815582
     [Google Scholar]
  39. WeiL. LeeD. LawC.T. ZhangM.S. ShenJ. ChinD.W. ZhangA. TsangF.H. WongC.L. NgI.O. WongC.C. WongC.M. Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC.Nat. Commun.2019101468110.1038/s41467‑019‑12606‑731615983
     [Google Scholar]
  40. RiniB.I. PalS.K. EscudierB.J. AtkinsM.B. HutsonT.E. PortaC. VerzoniE. NeedleM.N. McDermottD.F. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study.Lancet Oncol.20202119510410.1016/S1470‑2045(19)30735‑1 31810797
     [Google Scholar]
  41. ZhangY.N. WuX.Y. ZhongN. DengJ. ZhangL. ChenW. LiX. ZhongC.J. Stimulatory effects of sorafenib on human nonsmall cell lung cancer cells in vitro by regulating MAPK/ERK activation.Mol. Med. Rep.20149136536910.3892/mmr.2013.178224213303
     [Google Scholar]
/content/journals/cmp/10.2174/1874467216666230306101653
Loading
E2F1 Reduces Sorafenib’s Sensitivity of Esophageal Carcinoma Cells via Modulating the miR-29c-3p/COL11A1 Signaling Axis
Curr Mol Pharmacol 17, E060323214360 (2024); https://doi.org/10.2174/1874467216666230306101653
/content/journals/cmp/10.2174/1874467216666230306101653
/content/journals/cmp/10.2174/1874467216666230306101653
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): COL11A1; Drug sensitivity; E2F1; Malignant progression; miR-29c-3p; Sorafenib

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test